CELLULAR PROLIFERATION AND N-TERMINUS OF SV40 LARGE T ANTIGEN

SV40 大 T 抗原的细胞增殖和 N 末端

基本信息

  • 批准号:
    6575613
  • 负责人:
  • 金额:
    $ 22.84万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2002
  • 资助国家:
    美国
  • 起止时间:
    2002-03-01 至 2003-02-28
  • 项目状态:
    已结题

项目摘要

SV40 large T Antigen (T Ag) can serve as both a potent transforming oncoprotein and transcriptional activator. Several domains of T Ag have been identified .that contribute to the transforming and transactivation functions and, in some cases, these domains appear to overlap. However, it is not known whether the ability of T Ag to activate transcription from a wide variety of viral and cellular promoters contributes to cellular transformation. The dual effects of T Ag on the temperature sensitive Syrian hamster cell line, ts 13, may provide the t6ols to address this question. This cell line undergoes a GI arrest at the restrictive temperature due to a mutation in TAFII250, an essential component of the TFIID RNA polymerase Il complex. Transcription from a limited number of promoters including cyclin A is significantly reduced in tsl3 cells at the restrictive temperature. Expression of wild type TAF1I250 or SV40 large T Ag can override the cell cycle block and rescue the cyclin A promoter defects at the restrictive temperature. We propose to perform a genetic and biochemical analysis of the T Ag domains that are required to neutralize the cell cycle and transcriptional defects in tsl3 cells. We will examine whether the ability of T Ag to rescue the cyclin A promoter defect in tsl3 cells correlates with its ability to bind to certain TBP-Associated-Factors (TAFs) contained in the TFIID complex. Finally, we will examine the correlation between T Ag's ability to rescue the cyclin A promoter defect in tsl3 cells with its ability to override a GI/S arrest in these cells at the restrictive temperature. The goal here would be determine whether the specific domains of T Ag required for transactivation and rescue of the cyclin A promoter and for growth promotion in the tsl3 cells at the restrictive temperature were also required for cellular transformation. To the extent that this is so, the information extracted from these experiments could speak to the overall T Ag transforming mechanism.
SV40大T抗原(T Ag)是一种有效的转化癌蛋白和转录激活因子。已经鉴定了T抗原的几个结构域,它们有助于转化和转录激活功能,并且在某些情况下,这些结构域似乎重叠。然而,目前尚不清楚T抗原激活多种病毒和细胞启动子转录的能力是否有助于细胞转化。T抗原对温度敏感的叙利亚仓鼠细胞系ts 13的双重作用可能为解决这一问题提供了t6ols。该细胞系在限制性温度下由于TFII250(TFIID RNA聚合酶II复合物的必要组分)的突变而经历GI停滞。在限制性温度下,从有限数量的启动子(包括细胞周期蛋白A)的转录在tsl3细胞中显著减少。野生型TAF1I250或SV40大T抗原的表达可以克服细胞周期阻滞,并在限制性温度下挽救细胞周期蛋白A启动子缺陷。我们建议进行遗传和生物化学分析的T抗原结构域所需的中和细胞周期和转录缺陷的tsl3细胞。我们将研究T抗原是否有能力拯救细胞周期蛋白A启动子缺陷的tsl3细胞与其能力结合到某些TFIID复合物中所含的TBP相关因子(TAF)。最后,我们将研究T Ag的能力,以挽救在tsl3细胞中的细胞周期蛋白A启动子缺陷与其能力,以覆盖在这些细胞中的GI/S逮捕在限制性温度之间的相关性。这里的目标是确定细胞转化是否也需要细胞周期蛋白A启动子的反式激活和拯救以及在限制性温度下在ts13细胞中促进生长所需的T Ag的特异性结构域。在这种程度上,从这些实验中提取的信息可以说明整个T Ag转化机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

James A DeCaprio其他文献

Does a new polyomavirus contribute to Merkel cell carcinoma?
  • DOI:
    10.1186/gb-2008-9-6-228
  • 发表时间:
    2008-01-01
  • 期刊:
  • 影响因子:
    9.400
  • 作者:
    Kelly M Garneski;James A DeCaprio;Paul Nghiem
  • 通讯作者:
    Paul Nghiem

James A DeCaprio的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('James A DeCaprio', 18)}}的其他基金

CORE--MONOCLONAL ANTIBODY
核心--单克隆抗体
  • 批准号:
    6575619
  • 财政年份:
    2002
  • 资助金额:
    $ 22.84万
  • 项目类别:
CORE--MONOCLONAL ANTIBODY
核心--单克隆抗体
  • 批准号:
    6311522
  • 财政年份:
    2000
  • 资助金额:
    $ 22.84万
  • 项目类别:
CELLULAR PROLIFERATION AND N-TERMINUS OF SV40 LARGE T ANTIGEN
SV40 大 T 抗原的细胞增殖和 N 末端
  • 批准号:
    6311516
  • 财政年份:
    2000
  • 资助金额:
    $ 22.84万
  • 项目类别:

相似海外基金

Establishment of a Mouse NK Cell Line for Analyzing Tumor Infiltration Processes and Developing a Preclinical Model for Cancer Immunotherapy.
建立小鼠 NK 细胞系,用于分析肿瘤浸润过程并开发癌症免疫治疗的临床前模型。
  • 批准号:
    23K06731
  • 财政年份:
    2023
  • 资助金额:
    $ 22.84万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Proof of usefulness of PDX derived cell line
PDX 衍生细胞系的有用性证明
  • 批准号:
    23K06616
  • 财政年份:
    2023
  • 资助金额:
    $ 22.84万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A novel producer cell line for more efficient manufacturing of viral vector systems
用于更有效地制造病毒载体系统的新型生产细胞系
  • 批准号:
    10597799
  • 财政年份:
    2023
  • 资助金额:
    $ 22.84万
  • 项目类别:
Genestorian: a web application to document and trace genetic modifications in model organism and cell line collections.
Genestorian:一个网络应用程序,用于记录和追踪模型生物和细胞系集合中的遗传修饰。
  • 批准号:
    EP/Y024591/1
  • 财政年份:
    2023
  • 资助金额:
    $ 22.84万
  • 项目类别:
    Fellowship
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
用于生物制药细胞系开发的高性能细胞零日选择的人工智能辅助工具
  • 批准号:
    10672364
  • 财政年份:
    2022
  • 资助金额:
    $ 22.84万
  • 项目类别:
Developing a stable cell line expressing recombinant sclerostin
开发表达重组硬化素的稳定细胞系
  • 批准号:
    10385037
  • 财政年份:
    2022
  • 资助金额:
    $ 22.84万
  • 项目类别:
Development of Natural Killer (NK) Cell Line-Derived Extracellular Vesicles as a New Treatment for Cancer
开发自然杀伤 (NK) 细胞系衍生的细胞外囊泡作为癌症的新治疗方法
  • 批准号:
    10383462
  • 财政年份:
    2022
  • 资助金额:
    $ 22.84万
  • 项目类别:
A cell culture management platform to improve biomedical reproducibility by combining cell line tracking, low-cost genetic analysis, and riskassessment
细胞培养管理平台,通过结合细胞系追踪、低成本遗传分析和风险评估来提高生物医学重现性
  • 批准号:
    10483063
  • 财政年份:
    2022
  • 资助金额:
    $ 22.84万
  • 项目类别:
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
用于生物制药细胞系开发的高性能细胞零日选择的人工智能辅助工具
  • 批准号:
    10546865
  • 财政年份:
    2022
  • 资助金额:
    $ 22.84万
  • 项目类别:
Modulating expression of candidate genes to improve lentiviral vector production in stable cell line
调节候选基因的表达以提高稳定细胞系中慢病毒载体的产量
  • 批准号:
    2752732
  • 财政年份:
    2022
  • 资助金额:
    $ 22.84万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了